Newsfeed

High-Altitude Pulmonary Hypertension in Cattle May Unlock New Insights into Human PH
In a new study entitled “Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension,” researchers discovered two genetic variants responsible for Brisket disease in cattle which may provide clues to human conditions associated with pulmonary hypertension. The study was published in the journal Nature Communications. High-altitude pulmonary hypertension (HAPH) is the underlying cause of death of cattle in the Rock…
Early Decline in 6-minute Walk Test Distance Predicts Pulmonary Arterial Hypertension Deterioration
Results from a recent study published in the journal Respirology showed that an early decline in 6-minute walk test (6MWT) distance predicts deterioration of disease condition in patients with pulmonary arterial hypertension (PAH). The findings could provide new insights into effectively diagnosing and treating the disease using a completely non-invasive diagnostic approach. PAH is a condition that causes the pulmonary arteries to constrict ab…
Newly Discovered Molecular Mechanism May Be Cause of Pulmonary Hypertension
Researchers from Brigham and Women’s Hospital recently released findings from a study in which they have potentially uncovered the physiological mechanism leading to the development of Pulmonary Hypertension (PH). The study entitled, “Genetic and hypoxic alterations of the microRNA?210?ISCU1/2 axis promote iron–sulfur deficiency and pulmonary hypertension,” was published in the latest edition of EMBO Molecular Medicine. In a press release con…
PH Research Corner: Genetics and inheritance of PAH
In this issue of the Research Corner, we will focus on the genetics and inheritance of Pulmonary Arterial Hypertension (PAH). According to the most recent world health organization clinical classification, PAH divides into 3 categories. It can be: • idiopathic (with an unknown cause) • heritable (passed down in the family, previously known as familial) • associated (appears alongside another disorder). Genes functioning in an abnormal fa…
Selexipag Reduces Risk of Morbidity/Mortality Episodes in PAH
During the American College of Cardiology (ACC) Congress held this March (14-16) in San Diego, data from the pivotal Selexipag (Uptravi®) Phase III GRIPHON study was shared in an oral presentation. The presentation, entitled “Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study” was presented by Dr. Vallerie V. McLaughlin, showing that Selexipag significantly reduced the risk of a morbidity/m…
A Blueprint for Better Breathing
Ontario Lung Association Releases Framework for Lung Health Action Plan TORONTO, ON--(Marketwired - March 16, 2015) - Of the four chronic diseases responsible for four in five deaths in Ontario -- cancers, cardiovascular diseases, lung disease and diabetes -- lung disease is the only one without a dedicated province-wide strategy, this despite the ever-increasing human and economic burden of respiratory illness in this province. Bill 41, Lung H…
COPD Patients with PH are More Prone to Co-Morbidities
Researchers at the Cairo University in Egypt recently reported that patients with chronic obstructive pulmonary disease (COPD) can also develop co-morbidities as pulmonary hypertension and cardiac alterations. The study was published in the Egyptian Journal of Chest Diseases and Tuberculosis and is entitled “Detection of right sided heart changes and pulmonary hypertension in COPD patients.” COPD is a common progressive disease in which indivi…
Canadians with rare, complex and fatal lung disease fearful of one-size-fits-all approach to treatment
CDR recommendation limits specialists' ability to prescribe new medication VANCOUVER, March 5, 2015 /CNW/ - Canadians affected by pulmonary arterial hypertension (PAH) fear the threat of heart failure, or death, could soon be even more difficult to prevent given a recent recommendation to restrict patients' access to treatment. PAH is a rapidly-progressing and difficult-to-treat rare lung disease with no regard for race or age and is fatal wi…
Macitentan Significantly Reduces PAH-Related Hospitalization
In a new report entitled “Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial,” researchers describe the benefits of a Macitentan 10 mg dose in reducing the risk for hospitalization in patients with symptomatic pulmonary arterial hypertension. The report was published in the journal of the American College of Cardiac Foundation (JACC) Heart Failure. Pulmonary arterial hypertension (PAH) is a progressive, life-threatening …
#PHAware – Boy Raises Awareness For PH And Rare Disease Day On February 28
Lucas Van Wormer, a thirteen-year-old voice actor with PH working at Cartoon Network, along with his father, partnered with a credit union to raise awareness for pulmonary hypertension. The entertainment industry’s First Entertainment Credit Union along with celebrities like Courteney Cox, Florence Henderson, Laura Dern and Jeffrey Hayzlett are fighting for the cause as well. On a typical day, Lucas Van Wormer does voice overs at Cartoon Netwo…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png